Benzinga | May 17, 2021 04:31PM EDT

Amarin Highlights Presentation Of Scientific Findings For VASCEPA At American College Of Cardiology's 70th Annual Scientific Session

REDUCE-IT(r) patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipidemia, as defined by various high TG plus low HDL-C levels



Patients randomized to VASCEPA in EVAPORATE trial, in analyses of percent atheroma volume (PAV), had 55% lower coronary total plaque (TP) PAV and 61% lower coronary total non-calcified plaque (TNCP) PAV, compared with placebo

Amarin to Webcast Discussion of Data Presented at ACC.21 Today, Monday, May 17, 2021 at 4:30 p.m., Eastern Time

DUBLIN, Ireland and BRIDGEWATER, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of important VASCEPA(r) (icosapent ethyl) and its unique active ingredient-related scientific findings at ACC.21, the American College of Cardiology's 70th Annual Scientific Session, held virtually from May 15 -- 17, 2021, from a variety of academic collaborators based on research and analyses supported by Amarin.

"Cardiovascular disease continues to be the leading cause of death worldwide, with the economic and societal burden increasing each year," said Steven Ketchum, Ph.D., senior vice president, president of research & development, and chief scientific officer, Amarin. "As we strive to ease the strain on patients, their families, and healthcare systems around the world, we must continuously focus on the value that innovative therapies such as icosapent ethyl might offer at-risk patients. While we are proud that the clinical efficacy and safety of icosapent ethyl has been thoroughly reviewed and approved by regulatory authorities in the United States, Canada, and Europe as the only proven therapy for its indicated use in reducing cardiovascular risk, we are hopeful that our continued support of robust scientific presentation of the clinical effects and unique multifactorial mechanisms of action of icosapent ethyl will lead to a greater understanding and usage of this important product to help appropriate at-risk patients."